U.S. Stem Cell Inc (USRM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
45
About the Report
About the Report
Summary
U.S. Stem Cell Inc (U.S. Stem Cell), formerly Bioheart, Inc, is a biotechnology company that focuses on the discovery, development and commercialization of cell based therapeutics products. The company repairs and replaces damaged or aged tissue, cells and organs and restoring their normal function. The company's lead product MyoCell, is designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, to improve cardiac function in chronic heart failure patients. Its services includes the development of proprietary cell therapy products based on regenerative medicine and cell therapy training services, cell collection and cell storage services, sale of cell collection and treatment kits for humans and animals, and operation of a cell therapy clinic. U.S. Stem Cell is headquartered in Sunrise, Florida, the US.
U.S. Stem Cell Inc (USRM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
U.S. Stem Cell Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
U.S. Stem Cell Raises USD0.3 Million in Venture Financing 12
Private Equity 13
General American Capital to Invest up to USD5 Million in US Stem Cell 13
Partnerships 14
Bioheart Forms Joint Venture with Walter Bell 14
Licensing Agreements 15
Bioheart Enters Into Licensing Agreement With Allan Wu For Cancer-Related Immunotherapy Products 15
Bioheart Enters Into Licensing Agreement With Invitrx Therapeutics 16
Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 17
Debt Offering 18
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 12% Convertible Note Due 2016 18
U.S. Stem Cell Raises USD0.1 Million in Private Placement of 12% Convertible Note Due 2016 19
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 20
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 9.5% Notes 21
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 22
U.S. Stem Cell Raises USD0.33 Million in Private Placement of 8% Notes 23
U.S. Stem Cell Raises USD0.1 Million in Private Placement of Notes 24
U.S. Stem Cell Raises USD0.13 Million in Private Placement of Notes 25
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 8% Notes 26
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 8% Notes 27
Acquisition 28
Bioheart to Acquire Pavillion Scientific 28
Bioheart to Invest in Ascyrus Medical 29
U.S. Stem Cell Inc-Key Competitors 30
U.S. Stem Cell Inc-Key Employees 31
U.S. Stem Cell Inc-Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Joint Venture 32
Recent Developments 33
Financial Announcements 33
Nov 07, 2018: USRM posts 25% nine month revenue increase from 3Q 2017 33
Aug 08, 2018: USRM posts profitable results for second quarter 2018 34
May 09, 2018: U.S. Stem Cell Reports First Quarter Results 35
Apr 16, 2018: USRM Reports 2017 Financial Results 36
Aug 09, 2017: U.S. Stem Cell Reports Most Successful Financial Performance in the Company's History 37
Corporate Communications 38
Sep 11, 2018: USRM hires senior VP of US & international sales 38
Legal and Regulatory 39
Aug 28, 2017: FDA warns US Stem Cell Clinic of significant deviations 39
Product News 40
Mar 21, 2018: USRM Demonstrates 99% Reduction in Severity of Psoriasis Utilizing Autologous Stem Cells 40
Other Significant Developments 42
Apr 24, 2018: Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales 42
Feb 06, 2018: USRM Seeing Explosive Increase in Demand for Stem Cell Therapy 43
Aug 28, 2017: U.S. Stem Cell Clinic Acknowledges Warning Letter By The FDA and Responds 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
List of Figure
List of Figures
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
U.S. Stem Cell Inc, Deals By Therapy Area, 2012 to YTD 2018 9
U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
U.S. Stem Cell Raises USD0.3 Million in Venture Financing 12
General American Capital to Invest up to USD5 Million in US Stem Cell 13
Bioheart Forms Joint Venture with Walter Bell 14
Bioheart Enters Into Licensing Agreement With Allan Wu For Cancer-Related Immunotherapy Products 15
Bioheart Enters Into Licensing Agreement With Invitrx Therapeutics 16
Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 17
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 12% Convertible Note Due 2016 18
U.S. Stem Cell Raises USD0.1 Million in Private Placement of 12% Convertible Note Due 2016 19
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 20
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 9.5% Notes 21
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 22
U.S. Stem Cell Raises USD0.33 Million in Private Placement of 8% Notes 23
U.S. Stem Cell Raises USD0.1 Million in Private Placement of Notes 24
U.S. Stem Cell Raises USD0.13 Million in Private Placement of Notes 25
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 8% Notes 26
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 8% Notes 27
Bioheart to Acquire Pavillion Scientific 28
Bioheart to Invest in Ascyrus Medical 29
U.S. Stem Cell Inc, Key Competitors 30
U.S. Stem Cell Inc, Key Employees 31
U.S. Stem Cell Inc, Joint Venture 32
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.